News | November 14, 2024
AbbVie provides update on Phase 2 results for Emraclidine in schizophrenia
Emraclidine was well-tolerated with an adverse event profile consistent with Phase 1b trial
Emraclidine was well-tolerated with an adverse event profile consistent with Phase 1b trial
We are witnessing a steady and sustainable growth in the country as the Q2 revenue from operations increased by 31%
The GMP inspection assessed mammalian and microbial drug substance manufacturing facility sections
For Q2, Akums reported a consolidated total income of Rs. 1,046.6 crore
US Generics grew 5% to Rs. 467 Crores for the quarter
Partnership to Combine AbbVie's Oncology Expertise with EvolveImmune's Proprietary EVOLVE T-Cell Engager Platform to Develop Novel Multispecific Therapeutic Antibodies for Cancer
Reinforces position as first commercially approved contract development and manufacturing organization (CDMO) for ADCs in North America
Strengthening focus in Alzheimer's disease and neuroscience pipeline
Data demonstrate the importance of protecting against serious respiratory infections caused by respiratory syncytial virus, human metapneumovirus and COVID-19
GBM affects nearly 13,000 patients annually in the US and approximately 300,000 globally
Subscribe To Our Newsletter & Stay Updated
